{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:17:07Z","timestamp":1790806627397,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>We aim to report on somatostatin receptor (SSTR)-targeted molecular imaging and therapy in patients with advanced esthesioneuroblastoma (ENB).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>Five patients with ENB [Kadish stage D in 5\/5 (100%); Hyams grade 2 in 2\/5 (40%), grade 3 in 2\/5 (40%), undetermined in 1\/5 (20%)] underwent SSTR-directed PET\/CT. We quantified SSTR-avid tumor volume (TV), maximum SUV (SUV<jats:sub>max<\/jats:sub>), and target-to-background ratios (TBR). Based on imaging, peptide receptor radionuclide therapy (PRRT) along with dosimetry was also conducted. We recorded nephrotoxicity and hematotoxicity, including estimated glomerular filtration rate (eGFR), hemoglobin, leukocytes, and thrombocytes at baseline and after the last treatment cycle. We determined adverse events following Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Response and progression-free survival (PFS) was also evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>All 5 patients were rated positive on SSTR-PET\/CT. On a lesion-based level, we identified 32 SSTR-avid tumor sites with a median TV of 11.7\u00b110.8 and SUV<jats:sub>max<\/jats:sub> of 24.3\u00b112.8. TBR was 19.8\u00b19.7, indicating excellent image contrast. After median 4 (range, 2\u20136) cycles with a median of 7.7\u00a0GBq per cycle per patient, we observed no CTCAE grade 3 or 4 toxicity for leukocytes and thrombocytes and no significant CTCAE events for renal function. One patient (20%), however, developed reversible grade 3 anemia. Up to 11.8\u00a0Gy in tumor lesions were achieved. Partial response was recorded in 3\/5 (60%), stable disease in 1\/5 (20%), and progressive disease in 1\/5 (20%). The median PFS was 29 weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>SSTR-directed PET provided high image contrast in ENB, suggesting good read-out capabilities in this tumor type. PRRT was also feasible, along with an acceptable safety profile, thereby rendering SSTR-targeted theranostics a potential treatment option in advanced disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005717","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T06:00:45Z","timestamp":1740981645000},"page":"363-367","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Somatostatin Receptor-Directed Theranostics in Esthesioneuroblastoma"],"prefix":"10.1097","volume":"50","author":[{"given":"Yingjun","family":"Zhi","sequence":"first","affiliation":[{"name":"Otorhinolaryngology, Head and Neck Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5740-0537","authenticated-orcid":false,"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7927-6226","authenticated-orcid":false,"given":"Daniel","family":"Groener","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Clinic for Radiology and Nuclear Medicine, Goethe University Frankfurt, University Hospital, Frankfurt"},{"name":"University Cancer Center Frankfurt (UCT), Goethe University"},{"name":"German Cancer Consortium (DKTK), Partner Site Frankfurt\/Mainz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-9849","authenticated-orcid":false,"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9711-7835","authenticated-orcid":false,"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3694-6354","authenticated-orcid":false,"given":"Matthias","family":"Scheich","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Head and Neck Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Hackenberg","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Head and Neck Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4695-2483","authenticated-orcid":false,"given":"Joachim P.","family":"Steinbach","sequence":"additional","affiliation":[{"name":"University Cancer Center Frankfurt (UCT), Goethe University"},{"name":"German Cancer Consortium (DKTK), Partner Site Frankfurt\/Mainz"},{"name":"Dr. Senckenberg Insitute of Neurooncology, Goethe University, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-6046","authenticated-orcid":false,"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[{"name":"The Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD"},{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Klimek","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Clinic for Radiology and Nuclear Medicine, Goethe University Frankfurt, University Hospital, Frankfurt"},{"name":"University Cancer Center Frankfurt (UCT), Goethe University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinela","family":"Augustin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 5, Paracelsus Medical School, Nuernberg General Hospital, Nuernberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"R1-20250403","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/00016480310001295","article-title":"Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000","volume":"123","author":"Theilgaard","year":"2003","journal-title":"Acta Otolaryngol"},{"key":"R2-20250403","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1227\/00006123-199305000-00002","article-title":"Esthesioneuroblastoma: prognosis and management","volume":"32","author":"Morita","year":"1993","journal-title":"Neurosurgery"},{"key":"R3-20250403","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/hed.24770","article-title":"Prognostic significance of Kadish staging in esthesioneuroblastoma: an analysis of the National Cancer Database","volume":"39","author":"Konuthula","year":"2017","journal-title":"Head Neck"},{"key":"R4-20250403","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/alr.22373","article-title":"Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis","volume":"9","author":"Goshtasbi","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"R5-20250403","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1002\/hed.25209","article-title":"Esthesioneuroblastoma with distant metastases: Systematic review & meta-analysis","volume":"40","author":"Marinelli","year":"2018","journal-title":"Head Neck"},{"key":"R6-20250403","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.humpath.2018.05.013","article-title":"Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature","volume":"79","author":"Czapiewski","year":"2018","journal-title":"Hum Pathol"},{"key":"R7-20250403","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20250403","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.119.237990","article-title":"Efficacy of peptide receptor radionuclide therapy for esthesioneuroblastoma","volume":"61","author":"Hasan","year":"2020","journal-title":"J Nucl Med"},{"key":"R9-20250403","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus high\u2011dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"R10-20250403","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"R11-20250403","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R12-20250403","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/ph13030038","article-title":"[(68)Ga]Ga-DOTA-TOC: the First FDA-approved (68)Ga-radiopharmaceutical for PET imaging","volume":"13","author":"Hennrich","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"R13-20250403","first-page":"107","article-title":"Lutetium-177 DOTATATE production with an automated radiopharmaceutical synthesis system","volume":"3","author":"Aslani","year":"2015","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"R14-20250403","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/RLU.0000000000004870","article-title":"Somatostatin receptor-directed PET\/CT can differentiate between different subtypes of head and neck paragangliomas","volume":"48","author":"Zhi","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R15-20250403","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.117.193706","article-title":"Dose mapping after endoradiotherapy with (177)Lu-DOTATATE\/DOTATOC by a single measurement after 4 days","volume":"59","author":"Hanscheid","year":"2018","journal-title":"J Nucl Med"},{"key":"R16-20250403","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R17-20250403","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/RLU.0000000000000705","article-title":"Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT","volume":"40","author":"Makis","year":"2015","journal-title":"Clin Nucl Med"},{"key":"R18-20250403","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.3892\/etm.2016.3732","article-title":"Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: a case report","volume":"12","author":"Sabongi","year":"2016","journal-title":"Exp Ther Med"},{"key":"R19-20250403","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ons\/opy028","article-title":"Neuroradiological and neuropathological changes after 177Lu-Octreotate peptide receptor radionuclide therapy of refractory esthesioneuroblastoma","volume":"15","author":"Schneider","year":"2018","journal-title":"Oper Neurosurg (Hagerstown)"},{"key":"R20-20250403","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"key":"R21-20250403","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/COC.0000000000000903","article-title":"ACR-ACNM-ASTRO-SNMMI practice parameter for Lutetium-177 (Lu-177) DOTATATE therapy","volume":"45","author":"Love","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"R22-20250403","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0028-1096195","article-title":"Esthesioneuroblastoma: results and outcomes of a single institution\u2019s experience","volume":"19","author":"Ward","year":"2009","journal-title":"Skull Base"},{"key":"R23-20250403","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/RLU.0000000000005006","article-title":"Radiosensitizing favors response to peptide receptor radionuclide therapy in patients with highly proliferative neuroendocrine malignancies: preliminary evidence from a clinical pilot study","volume":"49","author":"Trautwein","year":"2024","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T02:45:10Z","timestamp":1743734710000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005717","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"2024-12-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}